INSIDE INFORMATION - ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION OF CERTAIN UNLISTED SHARES OF THE COMPANY

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.ImmuneOnco Biopharmaceuticals (Shanghai) Inc.宜明昂科生物医药技术（上海）股份有限公司 (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 1541) INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION OF CERTAIN UNLISTED SHARES OF THE COMPANY This announcement is made by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “Company” together with its subsidiaries the “Group”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “Listing Rules”) on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).Reference is made to the “Guidelines on Application for ‘Full Circulation’ of DomesticUnlisted Shares of H-share Companies” (CSRC Announcement [2023] No. 50) (《H股公司境内未上市股份申请「全流通」业务指引》(中国证监会公告[2023]50号)) (the “Guidelines”) issued by the China Securities Regulatory Commission (the “CSRC”) on August 10 2023 regarding the procedures of application by companies whose H shares are listed on the Stock Exchange for circulation of domestic unlisted shares (as defined under the Guidelines) on the Stock Exchange.The board (the “Board”) of directors (“Directors” and each a “Director”) of the Company is pleased to announce that the Company has recently received a filing notice issued by the CSRC (the “Filing Notice”) regarding the implementation of the H share full circulation of the Company. According to the Filing Notice the Company has completed the filing with the CSRC in respect of the implementation of conversion up to an aggregate of 120463260 unlisted shares of the Company (the “Unlisted Shares”) into H shares of the Company (“HShares”). The Filing Notice shall be valid for 12 months from May 14 2024.– 1 –The information of the implementation of the H share full circulation of the Company is set forth in the table below.Maximum number of Name of Shareholders Unlisted Shares to No. be converted 1. Dr. Tian Wenzhi (田文志) 35091495 2. Shanghai Zhangjiang Leading Initiating Venture Capital (Limited 25750000 Partnership) (上海张科领弋升帆创业投资中心(有限合伙)) 3. Beijing Lapam Healthcare Investment Centre (Limited Partnership) 19263240 (北京龙磐健康医疗投资中心(有限合伙)) 4. Jiaxing Changxian Enterprise Management L.P. (Limited Partnership) 7758630 (嘉兴昶咸企业管理合伙企业(有限合伙)) 5. Jiaxing Changyu Enterprise Management L.P. (Limited Partnership) 7419847 (嘉兴昶宇企业管理合伙企业(有限合伙)) 6. Suzhou Likang Equity Investment Centre (Limited Partnership) 7214085 (苏州礼康股权投资中心(有限合伙)) 7. Shanghai Zhangjiang Science & Technology Venture Capital Co. Ltd. 10862055 (上海张江科技创业投资有限公司) 8. Granite Peak Limited 2271082 9. Ningbo Yaluo Venture Capital Partnership (Limited Partnership) 2347150 (宁波雅罗创业投资合伙企业(有限合伙)) (formerly known as Shihezi Yaluo Equity Investment Partnership (Limited Partnership) (石河子市雅 罗股权投资有限合伙企业)) 10. Borah Peak Limited 1731836 11. Suzhou Lirun Equity Investment Centre (Limited Partnership) 753840 (苏州礼润股权投资中心(有限合伙)) Total 120463260 The Company will apply to the Stock Exchange for the listing of and permission to deal in such H Shares on the Main Board of the Stock Exchange (the “Conversion and Listing”).As at the date of this announcement the details of implementation plan of the Conversion and Listing have not been finalized. The Company will make further announcements on the progress of the Conversion and Listing in compliance with the requirements under Listing Rules and the applicable laws as and when appropriate.– 2 –The Conversion and Listing are subject to other relevant procedures as required by the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.By order of the Board ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Tian Wenzhi Chairman and Executive Director Hong Kong May 29 2024 As at the date of this announcement the Board of Directors comprises (i) Dr. Tian Wenzhi Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong Mr. Yu Zhihua and Mr. Yu Xiaoyong as non-executive Directors; and (iii) Dr. Zhenping Zhu Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.–3–